Back to today’s briefing

Story perspectives

FDA Phases Out Animal Testing for Drug Safety

4/11/2025

50 10

Summary

Story summary

The FDA is taking a groundbreaking step by phasing out animal testing for monoclonal antibodies and other drugs, opting instead for innovative human-relevant methods like artificial intelligence. This shift promises not only to enhance drug safety and cut research costs but also to improve animal welfare, marking a significant evolution in the pharmaceutical industry.

1 of 1

Story summary

The FDA is taking a groundbreaking step by phasing out animal testing for monoclonal antibodies and other drugs, opting instead for innovative human-relevant methods like artificial intelligence. This shift promises not only to enhance drug safety and cut research costs but also to improve animal welfare, marking a significant evolution in the pharmaceutical industry.